A double-Blind, Randomised, Placebo-Controlled, Multicentre, Dose-Escalating Study of AZD1305 Given Intravenoulsy for Cardioversion of Atrial Fibrillation

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-009862-15

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

Primary safety objective: To evaluate the dose-response relationship for QT effects of AZD1305 Primary efficacy objective: To demonstrate a dose-response relationship for AZD1305 given intravenously for conversion of AF to SR, and a statistically significant pair-wise difference for at least one of the dose levels of AZD1305 versus placebo


Critère d'inclusion

  • Atrial fibrillation clinically indicated for cardioversion